SCHEMBL5542017

SCHEMBL5542017

Fc1cccc(Nc2cc[c]cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.49
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 2/20 0.46
AR P10275 1/20 0.46
MAPT P10636 1/20 0.46
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
LMNA P02545 1/20 0.42
ABCG2 Q9UNQ0 2/20 0.41
EGFR P00533 1/20 0.41
FADS1 O60427 1/20 0.41
IDO1 P14902 1/20 0.41
TSHR P16473 2/20 0.40
TAAR1 Q96RJ0 1/20 0.40
CA12 O43570 1/20 0.40
MMP2 P08253 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
DEPTOR Q8TB45 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30675253 0.85 RAPGEF4 (0.61) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL392473 0.85 RAPGEF4 (0.61) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL1118619 0.83 MEN1 (0.68) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL31002670 0.83 MEN1 (0.68) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL23765069 0.81 RAPGEF4 (0.53) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL5543832 0.81 SOS1 (0.48) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL22923287 0.79 RAPGEF4 (0.52) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL3932395 0.76 MEN1 (0.40) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL5548434 0.76 RAPGEF4 (0.49) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL11896131 0.76 MEN1 (0.50) RAPGEF4MEN1KMT2AALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RAPGEF4 4025/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.